RxSight Stock Price, News & Analysis (NASDAQ:RXST) $34.97 +0.81 (+2.37%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$33.74▼$35.0450-Day Range$20.91▼$34.9752-Week Range$10.29▼$35.04Volume542,676 shsAverage Volume603,532 shsMarket Capitalization$1.25 billionP/E RatioN/ADividend YieldN/APrice Target$30.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media RxSight MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside12.2% Downside$30.71 Price TargetShort InterestHealthy4.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.09Based on 3 Articles This WeekInsider TradingSelling Shares$7.10 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.53) to ($1.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector613th out of 933 stocksOphthalmic Goods Industry4th out of 6 stocks 1.4 Analyst's Opinion Consensus RatingRxSight has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.71, RxSight has a forecasted downside of 12.2% from its current price of $34.97.Amount of Analyst CoverageRxSight has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.56% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RxSight has recently decreased by 9.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RXST. Previous Next 2.3 News and Social Media Coverage News SentimentRxSight has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for RxSight this week, compared to 1 article on an average week.Search Interest3 people have searched for RXST on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,098,444.00 in company stock.Percentage Held by Insiders21.13% of the stock of RxSight is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.51% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($1.53) to ($1.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -20.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -20.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 10.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About RxSight Stock (NASDAQ:RXST)RxSight, Inc., an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Read More RXST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RXST Stock News HeadlinesDecember 5, 2023 | msn.comMorgan Stanley Initiates Coverage of RxSight (RXST) with Overweight RecommendationDecember 5, 2023 | americanbankingnews.comRxSight (NASDAQ:RXST) Now Covered by Analysts at Morgan StanleyDecember 10, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 2, 2023 | americanbankingnews.comBakker Juliet Tammenoms Sells 145,068 Shares of RxSight, Inc. (NASDAQ:RXST) StockNovember 15, 2023 | finance.yahoo.comRxSight, Inc. (RXST) Recently Broke Out Above the 50-Day Moving AverageNovember 12, 2023 | finance.yahoo.comRxSight, Inc. (NASDAQ:RXST) Q3 2023 Earnings Call TranscriptNovember 11, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About RxSight's (NASDAQ:RXST) Cash Burn SituationNovember 9, 2023 | msn.comRxSight Non-GAAP EPS of -$0.19 beats by $0.16, revenue of $22.2M beats by $1.65MDecember 10, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 9, 2023 | finance.yahoo.comRxSight, Inc. Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 | markets.businessinsider.comHere's what Wall Street expects from RxSight's earnings reportOctober 27, 2023 | seekingalpha.comRxSight: Losing Altitude Despite 'Best Of Breed' PlatformOctober 26, 2023 | finance.yahoo.comRxSight, Inc. to Report Third Quarter Financial Results on November 9, 2023September 7, 2023 | finance.yahoo.comRxSight, Inc. (RXST) Crossed Above the 20-Day Moving Average: What That Means for InvestorsAugust 24, 2023 | finance.yahoo.comRxSight, Inc. (RXST) Interactive Stock Chart - Yahoo FinanceAugust 18, 2023 | fool.comRxSight (NASDAQ: RXST)August 16, 2023 | msn.comRxSight: Poised To Make Waves In Ophthalmic MarketAugust 14, 2023 | finance.yahoo.comWith 40% ownership, RxSight, Inc. (NASDAQ:RXST) has piqued the interest of institutional investorsAugust 12, 2023 | markets.businessinsider.comJ.P. Morgan Sticks to Their Buy Rating for RxSight (RXST)August 8, 2023 | msn.comOppenheimer Maintains RxSight (RXST) Outperform RecommendationAugust 8, 2023 | msn.comNeedham Reiterates RxSight (RXST) Buy RecommendationAugust 8, 2023 | markets.businessinsider.comWhere RxSight Stands With AnalystsAugust 8, 2023 | finance.yahoo.comRxSight, Inc. (NASDAQ:RXST) Q2 2023 Earnings Call TranscriptAugust 4, 2023 | benzinga.comRxSight's Earnings: A PreviewAugust 3, 2023 | msn.comRxSight (RXST) Price Target Increased by 11.03% to 30.80July 27, 2023 | finance.yahoo.comRxSight, Inc. to Report Second Quarter Financial Results on August 7, 2023July 12, 2023 | markets.businessinsider.comRxSight Is A Potential Acquisition Target: Analyst Highlights How LAL Revenue Mix Could Drive Share Price To $45+See More Headlines Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Ophthalmic goods Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RXST CUSIPN/A CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees292Year FoundedN/APrice Target and Rating Average Stock Price Target$30.71 High Stock Price Target$36.00 Low Stock Price Target$20.00 Potential Upside/Downside-12.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,760,000.00 Net Margins-71.87% Pretax Margin-71.81% Return on Equity-39.77% Return on Assets-30.17% Debt Debt-to-Equity RatioN/A Current Ratio8.87 Quick Ratio7.87 Sales & Book Value Annual Sales$49.01 million Price / Sales25.59 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book10.79Miscellaneous Outstanding Shares35,860,000Free Float28,284,000Market Cap$1.25 billion OptionableNot Optionable Beta1.07 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Ronald M. Kurtz M.D. (Age 60)President, CEO & Director Comp: $1.03MMs. Shelley B. Thunen (Age 69)CFO & Assistant Secretary Comp: $651.36kDr. Ilya Goldshleger Ph.D. (Age 48)Chief Operating Officer Comp: $657.81kMr. Eric J. Weinberg (Age 62)Chief Commercial Officer Comp: $638.9kMs. Rebecca WillistonVice President of Accounting & FinanceMr. Matt Haller Ph.D.Chief Technology OfficerAlex HuangInvestor RelationsMr. Roy FreemanVice President of MarketingMs. Caroline VaughnVice President of Human ResourcesMr. Scott GainesSenior VP of Commercial Operations & Business ProcessMore ExecutivesKey CompetitorsWarby ParkerNYSE:WRBYSTAAR SurgicalNASDAQ:STAAXencorNASDAQ:XNCRScholar RockNASDAQ:SRRKProtagonist TherapeuticsNASDAQ:PTGXView All CompetitorsInsiders & InstitutionsBakker Juliet TammenomsSold 145,068 sharesTotal: $4.30 M ($29.62/share)Deutsche Bank AGSold 55,367 shares on 11/24/2023Ownership: 0.038%Morgan StanleySold 295,671 shares on 11/16/2023Ownership: 3.378%Tudor Investment Corp Et AlSold 57,011 shares on 11/16/2023Ownership: 0.078%The Manufacturers Life Insurance Company Bought 4,034 shares on 11/15/2023Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions RXST Stock Analysis - Frequently Asked Questions Should I buy or sell RxSight stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RXST shares. View RXST analyst ratings or view top-rated stocks. What is RxSight's stock price target for 2024? 5 Wall Street analysts have issued 1 year price targets for RxSight's shares. Their RXST share price targets range from $20.00 to $36.00. On average, they expect the company's share price to reach $30.71 in the next twelve months. This suggests that the stock has a possible downside of 12.2%. View analysts price targets for RXST or view top-rated stocks among Wall Street analysts. How have RXST shares performed in 2023? RxSight's stock was trading at $12.67 on January 1st, 2023. Since then, RXST stock has increased by 176.0% and is now trading at $34.97. View the best growth stocks for 2023 here. When is RxSight's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our RXST earnings forecast. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.07. The firm had revenue of $22.20 million for the quarter, compared to analysts' expectations of $20.81 million. RxSight had a negative trailing twelve-month return on equity of 39.77% and a negative net margin of 71.87%. What ETF holds RxSight's stock ? Invesco Dorsey Wright Healthcare Momentum ETF holds 53,792 shares of RXST stock, representing 1.07% of its portfolio. When did RxSight IPO? (RXST) raised $125 million in an IPO on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share. Who are RxSight's major shareholders? RxSight's stock is owned by a variety of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (6.84%), Lord Abbett & CO. LLC (4.57%), Morgan Stanley (3.38%), JPMorgan Chase & Co. (1.54%), Atika Capital Management LLC (1.43%) and Federated Hermes Inc. (0.88%). Insiders that own company stock include Bakker Juliet Tammenoms, Jesse Anderson Corley and Shweta Maniar. View institutional ownership trends. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RXST) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.